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ABSTRACT
Background: Migraine is a highly prevalent and frequently disabling condition.
Its etiology is multifactorial, involving various genetic, environmental and
inflammatory factors, hence, it is reasonable to assess the serum C-reactive
protein level and monocyte count in migraine.
Objective: Assessment of the serum C-reactive protein level and monocyte count
among migraineurs.
Subjects and Methods: This case-control prospective study was conducted on
twenty-seven migraineurs attended the Neurology Outpatient Clinic of Zagazig
University Hospital and diagnosed according to The International Classification
of Headache Disorders, (3rd edition) and twenty-seven controls. All subjects
underwent: Detailed medical, neurological and headache history, complete
general and neurological examination and investigations: complete blood count
(including monocyte count), liver and kidney function tests, lipid profile, blood
glucose level, erythrocyte sedimentation rate, C-reactive protein level ,
electrocardiography and computed tomography brain and/or magnetic resonance
imaging brain when indicated.
Results: Migraine patients without preventive treatment had higher C-reactive
protein level and monocytes count in comparison to others with treatment
however; the difference was not a statistically significant. We can notice also that
there is no correlation between monocyte count and C-reactive protein. In our
study the monocyte count showed a statistically significant higher values in case
group than control also, was a statistically significant area under the curve and
cut off of monocyte regarding detection of cases >550, with sensitivity,
specificity, +ve predictive, -ve predictive and accuracy were 81.5%, 59.3%,
66.7%, 76.1% and 70.3% respectively.
Conclusion: Our findings suggest that the elevated C-reactive protein level and
monocyte count are associated with migraine.
Key words; C-reactive protein, Monocyte count, Migraine.

INTRODUCTION
igraine could be an extremely current
and frequently disabling condition that
poses an interesting medical and economic
burden on human society. It is a complex,
multifactorial neurological disorder affecting
about 10% of the adult population worldwide
and it's the second most prevalent
neurological disorder and therefore the causal
agent of incapacity in below the 50s [1].
Migraine is defined as a perennial
unilateral headache disorder lasting 4–72
hours, characterized by pulsing pain of
moderate or severe intensity, related to nausea
and/or photophobia and phonophobia [2].
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Migraine has two major subtypes. A
migraine with aura (classic type) is primarily
characterized by the transient focal neurologic
symptoms that usually precede or sometimes
accompany a headache and migraine without
aura (common type) [3].
Migraine etiology is complex,
involving both numerous genetic and
environmental factors, however scientists
think about three necessary mechanisms for
its pathophysiology including: inflammatory,
neurological and cardiovascular impairments
[4]. It is accompanied by the evidence that a
migraine is considerably related to
cardiovascular
disorders,
coronary
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cardiopathy and stroke [5].
Among the varied inflammatory
biomarkers, the C - reactive protein (CRP)
and monocyte count are powerfully related to
cardiovascular
disorders,
coronary
cardiovascular disease and cerebral stroke [6].
Hence, it's reasonable to investigate the role
of the serum C - reactive protein (CRP) level
and monocyte count during a migraine.
AIM OF THE WORK
Assessment of the serum CRP level
and monocyte count among migraine patients.
SUBJECTS AND METHODS
This case-control prospective study was
conducted on twenty-seven migraineurs who
attended the Neurology Outpatient’s Clinics
of Neurology Department in Zagazig
University Hospital during the period (from
November 2017 to April 2019) and twentyseven age and sex-matched healthy controls.
Written informed consent was obtained from
all participants, the study was approved by the
research ethical committee of Faculty of
Medicine, Zagazig University. The study was
done according to The Code of Ethics of the
World Medical Association (Declaration of
Helsinki) for studies involving humans.
The subjects included in the study: Case
group:
Migraine
patients
diagnosed
according to The International Classification
of Headache Disorders, 3rd edition [7] and
Control group: Healthy individuals with age
and sex matching and no history of migraine
or in their first degree relatives.
The inclusion criteria: Age of the
subjects must be above 18 years old. The
exclusion criteria: Applied to both case and
control groups include: Obesity with body
mass
index
(BMI)
≥
30
kg/m2,
hypercholesterolemia, hypertension, diabetes
mellitus, active infection, history of
cardiovascular disease, subjects on antiinflammatory drugs, pregnancy & lactation,
immune diseases and smoking.
The ethical consideration: According to
ethical rules of institutional review board
(IRB) Informed consent from patients about
the study was obtained and no harmful
maneuvers performed or used for any
patients.
All subjects in this study underwent:
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Detailed medical, neurological and headache
history was taken, complete general
examination and complete neurological
examination.
The laboratory investigations: The
samples were collected through 72 hours from
last migraine attack. Routine laboratory
investigations include: Complete Blood Count
(CBC): Including Monocyte count, liver and
kidney function tests, lipid profile, blood
glucose level and Erythrocyte Sedimentation
Rate (ESR). Specific laboratory investigations
include: C-reactive protein (CRP) test,
electrocardiography (ECG) and neuroimaging
brain
computed
tomography (CT)
and/or magnetic resonance imaging (MRI)
brain when indicated.
Statistical Analysis
Data collected throughout history, basic
clinical examination, laboratory investigations
and outcome measures coded, entered and
analyzed using Microsoft Excel software.
Data were then imported into Statistical
Package for the Social Sciences (SPSS
version 20.0) software for analysis [8].
RESULTS
Table (1): C-reactive protein (CRP) and
monocyte distribution between groups.
From table (1) we can notice that migraine
patients had a statistically significant higher
monocytes count in comparison to control.
The patient showed higher levels of CRP than
control however; the difference was not
reaching the statistically significance.
Table (2): Area under the curve and cut off
of monocyte regarding detection of
migraine.
From table (2) we can notice that there was
a statistically significant area under the curve
with cutoff >550.
Table (3): Association between monocyte
cutoff and migraine.
From table (3) we can notice that there was
a statistically significant association between
monocyte cutoff and cases (P = 0.002).
Table (4): Validity of monocyte cutoff for
detection of migraine.
From table (4) we can notice that
sensitivity, specificity, +ve predictive, -ve
predictive and accuracy were 81.5%, 59.3%,
66.7%, 76.1%
and 70.3% respectively.
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Table (1): C-reactive protein (CRP) and monocyte distribution between groups
Case
Control
t/ Mann
P
(N=27)
(N=27)
Whitney
CRP
5.1±2.8
4.17±1.17
1.688
0.097
Monocyte
677.77±145
533.3±188.1
3.160
0.003*
CRP: C-reactive protein
* : Statistically highly significant
P value was set at <0.05 for significant results
Table (2): Area under the curve and cut off of monocyte regarding detection of migraine
Area Under the Curve
Test Result Variable(s): Monocyte
Area
Cutoff
P
95% Confidence Interval
Lower Bound
Upper Bound
0.728
>550
0.004*
0.590
0.866
* : Statistically highly significant
P value was set at <0.05 for significant results
Table (3): Association between monocyte cutoff and migraine
Groups
Total
X2
P
Control
Case
N
16
5
21
9.42 0.002*
%
59.3%
18.5%
38.9%
N
11
22
33
%
40.7%
81.5%
61.1%
N
27
27
54
%
100.0%
100.0%
100.0%
(X2): Chi square test
* : Statistically highly significant
P value was set at <0.05 for significant results

Monocyte

cutoff
<550
>550
Total

Kappa agreement
0.52

Table (4): Validity of monocyte cutoff for detection of migraine.
Sensitivity

Specificity

81.5%

59.3%

Monocytes

DISCUSSION
Migraine could be a primary headache
disorder characterized by perennial headaches
that are moderate to severe. Typically, the
headaches have an effect on one half of the
head, are beating in nature, and last from two
to seventy two hours [9].
The precise mechanisms stay unclear,
however a neurovascular inflammation as a
part of the complicated pathophysiological
method has been steered. Migraines also are
believed to be due to a combination of
environmental and genetic factors [10].
Elsheikh B., et al
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+VE
Predictive
66.7%

-VE
predictive
76.1%

Accuracy
70.3%

Among
the
varied
inflammatory
biomarkers, the C - reactive protein (CRP)
and monocyte count are powerfully related to
vessel disorders, coronary cardiovascular
disease and cerebral stroke [6], [11], hence,
it's reasonable that's why the study was
chosen to be conducted to investigate the role
of the CRP level and monocyte count in
migraine.
Our study showed higher levels of CRP in
cases than controls that was distributed as
5.1±2.8 in case group and 4.17±1.17 in
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control respectively, however the difference
did not reach the statistically significance.
This in agreement with a review of studies
published between 2006 and 2014 indicated
higher CRP levels in people with migraine
than in controls [12].
Furthermore, study conducted by Yildiz et
al., [13] found that CRP level was
considerably higher in migraine group, and
reported that higher serum inflammatory
markers support the role of inflammation in
migraine pathogenesis.
The association of CRP level with
migraine has been shown in a little of case
control studies of migraine with vascular risk
factors [14], [15], [16].
Avci et al., [15] reported that serum CRP
levels were considerably higher in migraine
patients than control subjects.
In contrast with the present study, another
study reported that no association between
CRP levels and migraine [16].
The effectiveness of biomarkers is often
measured in terms of their sensitivity,
specificity and by making receiver in
operation characteristic curves, which permit
for the calculation of the area under the curve.
Sensitivity is commonly defined as the
proportion of a population with a disease in
whom the check in question offers a positive
result. Specificity is that the proportion of that
population while not the sickness in whom the
check offers a negative result. Biomarkers
that are sensitive have low false-negative rates
and people that are extremely specific have
low false-positive rates. Optimally, a good
biomarker are going to be each sensitive and
specific. It’s terribly rare that a diagnostic
biomarker is strictly present or absent. Much
more commonly, the presence of a biomarker
is measured as a continuous variable and
cutoffs are defined along that continuum to
establish the presence or absence of disease
[17].
In the present study the monocyte count
showed a statistically significant higher
values in case group than control also, was a
statistically significant area under the curve
and cut off of monocyte regarding detection
of cases >550 which means when monocyte
count more than 550 is significant as an
inflammatory marker in migraine patients.
Elsheikh B., et al
https://digitalcommons.aaru.edu.jo/zumj/vol27/iss3/17

Doi: 10.21608/zumj.2020.17420.1548

There was significant association between
monocyte cutoff and cases (P = 0.002), with
sensitivity, specificity, +ve predictive, -ve
predictive and accuracy were 81.5%, 59.3%,
66.7%, 76.1% and 70.3% respectively.
This adapted to study led by Peng et al.,
[18] who announced that monocyte count in
patients with migraine was higher than
control groups.
Pusic et al., [19] reported that microglia
may play an important role in neuropathic
pain
and
migraine
initiation
by
neuroinflammatory mediators, and a thought
of current monocytes as direct microglia
orthologous
was
introduced
in
neuroinflammatory processes. Additionally,
neuroinflammation will be mirrored by
peripheral monocytes changes in some
neurologic diseases.
In fact, monocytes in peripheral circulation
will populate the central nervous system and
differentiate into microglia below conditions
of neuropathic inflammation and a potential
relationship between increased levels of CRP
and migraine has been well established [12].
Taken together, the above evidences cause a
hypothesis with reference to peripheral
monocyte count and CRP in patients with
migraine.
Therefore, our findings suggest that
elevated monocyte count and CRP are
associated with migraine.
CONCLUSION
In conclusion the present study showed a
statistically significant higher values of the
monocyte count in case group than control
which mean that monocyte count may play a
role in inflammatory theory of migraine as a
biomarker in pathogenesis, diagnosis and
prognosis of migraine. The higher levels of Creactive protein as a non-specific marker of
inflammation in cases than controls also
support the inflammatory theory of migraine.
These markers may help us to understand the
pathophysiology of migraine also, because the
low cost of these tests that commonly used,
they may be beneficial for guarding migraine
patients against long-term comorbidities.
The limitations were a relatively small
sample size in the present study. In
addition, the levels of monocyte count
were not assessed in other migraine
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subgroups.
Our recommendations are future
researches for better understanding of
mechanisms of migraine and pathogenesis to
reveal the actual underlying causes and the
association
between
migraine
and
inflammatory biomarkers for developing
better treatment with satisfied outcome.
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